Arjunolic Acid

Arjunolic acid is a pentacyclic triterpenoid compound derived from Terminalia arjuna bark that provides cardiovascular and neuroprotective effects. It works primarily through PPARα activation and anti-inflammatory pathways to protect heart and brain tissue.

Origin & History

Arjunolic acid is a pentacyclic triterpenoidal saponin isolated primarily from the bark of Terminalia arjuna, a tree used in traditional Ayurvedic medicine. It is extracted through solvent-based methods followed by chromatographic purification techniques and is also found in Terminalia ivorensis and fruits of Akebia trifoliata.

Historical & Cultural Context

Arjunolic acid from Terminalia arjuna bark has been central to Ayurvedic cardioprotective remedies for centuries, traditionally used for preventing myocardial necrosis and supporting heart health. The compound is also found in Akebia trifoliata fruits, which are used in Traditional Chinese Medicine for psychiatric disorders.

Health Benefits

• Cardiovascular protection: Reduced cardiac hypertrophy markers and improved heart function (38.53% to 46.67% fractional shortening) in animal models through PPARα activation
• Neuroprotection: Decreased brain infarct size and neurological deficits in rat stroke models at 10-20 mg/kg doses
• Anti-cancer activity: Reduced breast cancer tumor burden by ~89% in DMBA-induced rat models, comparable to tamoxifen
• Anti-depressive effects: Ameliorated depressive behaviors and increased BDNF/5-HT levels in LPS-induced mouse models
• Anti-inflammatory action: Shifted microglial phenotype to M2 and modulated cytokines (reduced TNF-α, IL-6; increased IL-10) in preclinical studies

How It Works

Arjunolic acid activates peroxisome proliferator-activated receptor alpha (PPARα), which regulates fatty acid oxidation and reduces cardiac hypertrophy markers. The compound also inhibits pro-inflammatory cytokines and reduces oxidative stress through modulation of nuclear factor-kappa B (NF-κB) signaling. Additionally, it enhances mitochondrial function and supports cellular energy metabolism in cardiac and neural tissues.

Scientific Research

Current evidence for arjunolic acid is limited to preclinical animal and cellular studies, with no human clinical trials, RCTs, or meta-analyses identified. Key animal studies include cardiac hypertrophy models in rats, focal cerebral ischemia-reperfusion studies (n=8-10 per group), and a 121-day breast cancer study in DMBA-induced rats showing 89% tumor reduction at 1 mg/kg dosing.

Clinical Summary

Research on arjunolic acid is primarily limited to animal studies with promising cardiovascular results. Rat models demonstrated 38.53% to 46.67% fractional shortening improvement in heart function and reduced cardiac hypertrophy markers through PPARα activation. Stroke studies in rats showed decreased brain infarct size and improved neurological outcomes at 10-20 mg/kg doses. Human clinical trials are currently lacking, making evidence strength preliminary despite encouraging preclinical data.

Nutritional Profile

Arjunolic Acid is a pure triterpenoid saponin compound (C30H48O5, molecular weight ~496.7 g/mol), not a whole food ingredient, so classical macronutrient/micronutrient profiling does not apply. Key bioactive profile: Primary constituent is the pentacyclic triterpenoid scaffold with three hydroxyl groups (-OH) at C-2α, C-3β, and C-23 positions, and a carboxylic acid group at C-28, conferring amphiphilic properties. Isolated predominantly from the bark of Terminalia arjuna at concentrations of approximately 0.1–0.5% dry weight of bark extract. Bioactive concentration thresholds established in preclinical models: 10–20 mg/kg body weight (oral/intraperitoneal) for neuroprotective and cardioprotective effects; ~50 mg/kg for anti-tumor activity in rodent models. No caloric, protein, fat, fiber, vitamin, or mineral content is applicable as it is an isolated phytochemical. Bioavailability: Oral bioavailability is considered moderate-to-low due to its high molecular weight and polarity; first-pass hepatic metabolism is likely significant. Lipophilicity (estimated LogP ~2.8–3.5) suggests partial passive diffusion across lipid membranes. Nanoformulation and phospholipid complexation have been explored to enhance bioavailability. PPARα agonist activity confirmed at molecular level, supporting its metabolic and cardioprotective mechanism of action.

Preparation & Dosage

Preclinical studies used: 10-20 mg/kg orally for 7 days (neuroprotection), 1 mg/kg for 121 days (cancer), with doses determined by response curves in cardiac models. No human dosage data or standardized extract preparations are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Terminalia arjuna extract, CoQ10, Resveratrol, Curcumin, Quercetin

Safety & Interactions

Safety data for arjunolic acid is limited due to lack of human clinical trials. Animal studies at therapeutic doses (10-20 mg/kg) showed no significant adverse effects, but long-term safety remains unknown. Potential interactions with cardiovascular medications and PPARα agonists like fibrates should be considered due to overlapping mechanisms. Pregnant and breastfeeding women should avoid use due to insufficient safety data.